Navigation Links
Mylan Launches First Generic Version of Femara® Tablets
Date:4/25/2011

PITTSBURGH, April 25, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Letrozole Tablets USP, 2.5 mg, under a previously announced settlement and license agreement with Novartis. Mylan was the first company to have filed a substantially complete ANDA containing a Paragraph IV certification for Letrozole Tablets and will market the product with a period of exclusivity.

Letrozole Tablets are the generic version of Novartis' Femara® Tablets, an adjuvant treatment for postmenopausal women with hormone receptor-positive early stage breast cancer. This product had U.S. sales of approximately $682 million for the 12 months ending Dec. 31, 2010, according to IMS Health.

Currently, Mylan has 165 ANDAs pending FDA approval representing $98.5 billion in annual sales, according to IMS Health. Forty-six of these pending ANDAs are potential first-to-file opportunities, representing $25.9 billion in annual brand sales, for the 12 months ending June 30, 2010, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R)
2. Mylan Receives FDA Approval for Generic Version of Parkinsons Treatment Sinemet(R)
3. Mylan Schedules Third Quarter 2009 Financial Results Conference Call and Live Webcast
4. Mylan Receives FDA Approval for Generic Version of Anticonvulsant Topamax(R) Sprinkle Capsules
5. Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
6. Mylan Receives Approval for Generic Version of GoLytely(R)
7. Mylan Declares Quarterly Preferred Stock Dividend
8. Mylan Pre-Pays All Scheduled 2011 Term-Loan Borrowings
9. Mylan Confirms First-to-File Patent Challenge Relating to Vytorin(R) Cholesterol Medication
10. Mylans President of Europe, Middle East and Africa Elected President of European Generic Medicines Association
11. Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories New Drug Application (NDA) for Efavirenz Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... and PUNE, India , January 24, ... by Allied Market Research, titled, "Acidity Regulators Market - ... market for acidity regulators was valued at $4,456 million in 2015, ... a CAGR of 7.96% from 2016 to 2022. Asia-Pacific ... to maintain its lead, followed by North America ...
(Date:1/24/2017)... SAN FRANCISCO , January 24, 2017 ... reach a value of USD 3.8 billion by 2025, ... Inc. The market growth can be attributed to the ... awareness about early diagnosis of micro calcifications in breast ... Cancer Foundation, CDC, and Breast Cancer Organization are promoting ...
(Date:1/24/2017)... For today, Stock-Callers.com scans the following Biotechnology companies: ... Inc. (NASDAQ: ALDR ), BioDelivery Sciences International Inc. ... EGLT ). These equities are part of the Healthcare ... , 2017, with the NYSE Health Care Index dropping about ... 500 also were down 0.3% as a group. These stocks ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 24, 2017 , ... ... technology offering, Processing Assurance Control Equipment (PACE), at the International Production and Processing ... PeroxyChem’s booth will highlight the new technology that is used in poultry processing ...
(Date:1/24/2017)... , ... January 24, 2017 , ... ... to the semi-final round of the 2017 Cupid's Cup Entrepreneurship Competition. Chaired by ... 12th year in 2017. The entrepreneurs will showcase their businesses on February 6, ...
(Date:1/24/2017)... ... , ... Bellus Medical, a leader in medical aesthetics, today announced that Marek ... Dr. Dobke will provide physician oversight for in-house clinical studies and hands-on device training, ... and Associate Professor of Surgery at UC San Diego Health and is a board ...
(Date:1/24/2017)... ... 2017 , ... Inspiration, Community & Mentorship – Top Students ... Fordham Institute’s High Stakes for High Achievers offer recommendations for how ... high-achieving students as a subgroup and reporting their results separately. Top students and ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... unveiled its latest award-winning bottles, designed specifically to optimize the drinking experience for ... Agua is renowned for introducing the world’s first untouched bottled water purposed exclusively ...
Breaking Medicine News(10 mins):